Alice Shaw highlights the development and clinical considerations for use of first- and next-generation ALK inhibitors in NSCLC, plus ongoing research.
Alice T. Shaw, MD, PhD
Advertisement
Articles by Alice T. Shaw, MD, PhD
Advertisement
Latest Updated Articles
Newer Targeted Agents in NSCLC: ALK InhibitorsPublished: June 13th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
